Background Prostate cancer mortality rates for African-Americans are much higher than Caucasians and a similar trend is observed for prostate cancer survival. Data on recently immigrated African-descent men are lacking. Methods Using cancer registry data from Brooklyn, NY and two countries in the Caribbean (Guyana and Trinidad & Tobago), survival rates were estimated. We also examined whether Black race or Caribbean birth-place predict prostate cancer survival among males living in the United States (US). Results The Caribbean cases were diagnosed at a later age than those in the US (Guyana: 74.5yrs, Trinidad & Tobago: 72.4yrs, Brooklyn: 65.8yrs). Patients in the Caribbean had a worse 5-year survival rate compared to those in the US (41.6% vs. 84.4%) but for immigrant Caribbean-born males living in the US the five-year survival rate was not significantly different from African-Americans (78.1%, 95% CI: 70.9–83.7% vs. 81.4%, 95% CI: 69.5–89.1%, p = 0.792). The risk of death for Caribbean born was more than three times higher than US-born men (HR: 3.43, 95% CI: 2.17–5.44, adjusted for ethnicity, stage and mean age of diagnosis). A mean age of diagnosis greater than 65 years old and stage IV disease, but not ethnicity, were found to be independently associated with the risk of death. Conclusion The survival disadvantage for Caribbean born patients may be partly due to later diagnosis. Interventions focused on screening, education about the disease and early detection could potentially reduce cancer mortality in this population.
This study demonstrates that grouping together US-born and foreign-born black patients may mask important differences within the black population. The observed differences between US-born and foreign-born black patients may be associated with variations in environmental and other lifestyle exposures that contribute to more aggressive histologic types.
BackgroundProstate cancer is the sixth leading cause of death from cancer among men worldwide. We have previously reported that prostate cancer survival rates for Caribbean-born males in the US was similar to survival rates of African-Americans and was higher than their counterparts diagnosed in the Caribbean. However, it is not clear whether differences in mortality could be attributed to differences in treatment.MethodsThis current analysis seeks to further explore reasons for the geographic variation of prostate cancer survival for Caribbean-born men. This analysis included 2,554 Black newly diagnosed prostate cancer cases (960 cases diagnosed in the US and 1,594 cases diagnosed in the Caribbean). Clinical data were extracted from the cancer registry and clinical charts.ResultsThere were noted differences in the pattern of treatment for each place of birth category when stratified according to disease stage at diagnosis. Among the patients diagnosed with early-intermediate disease (stage I-III) the majority of US-born Brooklyn men were treated with surgery only (31%) and a similar pattern was observed for Caribbean-born Brooklyn men (35%). In contrast, the majority of Caribbean-born Trinidad & Tobago men were treated with hormone therapy (31%).Caribbean-born men diagnosed in the Caribbean had a significantly higher risk of death from prostate cancer (Adjusted Hazard [AdjHR]: 3.7, 95% Confidence Interval [CI]: 2.8-5.0) when compared with the risk of death for Caribbean-born males diagnosed in the US. This observation was consistent for each treatment group with the exception of the cases treated with hormone therapy only. For these cases, there was no difference in the risk of death between Caribbean-born males diagnosed in the Caribbean (AdjHR: 1.4, 95% CI: 0.8-2.6) compared to Caribbean-born males diagnosed in the US.ConclusionsIn addition to difference in access and utilization of screening, differences in treatment strategy may also be a strong predictor of outcome for Caribbean-born males diagnosed with prostate cancer. Further studies are needed to confirm these findings. In addition, other environmental factors related to survival that was not considered in this analysis also need to be investigated.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.